maropitant has been researched along with Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukazawa, E; Harada, K; Ichimata, M; Kobayashi, T; Matsuyama, F; Nakano, Y | 1 |
| Cartagena-Albertus, JC; Engel Manchado, J; Moise, A; Montoya Alonso, JA; Moya García, S | 1 |
1 trial(s) available for maropitant and Neoplasms
| Article | Year |
|---|---|
Assessment of the administration of maropitant and loperamide to dogs with cancer for the prevention and reduction of adverse effects associated with the administration of paclitaxel.
Topics: Animals; Antidiarrheals; Antiemetics; Antineoplastic Agents, Phytogenic; Diarrhea; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Loperamide; Male; Neoplasms; Paclitaxel; Quinuclidines; Random Allocation; Vomiting | 2019 |
1 other study(ies) available for maropitant and Neoplasms
| Article | Year |
|---|---|
Evaluation of adverse events in small-breed dogs treated with maropitant and a single dose of doxorubicin.
Topics: Animals; Diarrhea; Dog Diseases; Dogs; Doxorubicin; Neoplasms; Neutropenia; Prospective Studies; Quinuclidines; Vomiting | 2022 |